Oncobiologics

About Oncobiologics

Initially incorporated as Oncobiologics, Inc. in 2010, the company was founded by Pankaj Mohan, Ph.D., to address the growing market for cost-effective biologic therapies. The firm began as a clinical-stage biopharmaceutical company focused on developing and commercializing a broad pipeline of complex monoclonal antibody (mAb) biosimilar therapeutics for immunology and oncology. A key component of its early strategy was the proprietary BioSymphony™ Platform, an integrated system designed for the efficient, cost-effective, and accelerated development and manufacturing of high-quality mAb biosimilars. This platform was also offered as a contract development and manufacturing (CDMO) service to other biologics companies.

A significant strategic pivot occurred in December 2018, when Oncobiologics rebranded as Outlook Therapeutics, Inc. (NASDAQ: OTLK). This name change signaled a shift in focus from a diversified biosimilar pipeline to the specialized development of its lead candidate, ONS-5010, for ophthalmic indications. ONS-5010, now known as LYTENAVA™ (bevacizumab-vikg), is a proprietary ophthalmic formulation of bevacizumab designed to treat retinal diseases such as wet age-related macular degeneration (wet AMD). The company's business model transitioned from being a broad biosimilar developer to a specialized ophthalmic biopharmaceutical firm centered on securing regulatory approval and commercializing LYTENAVA™.

The company's revenue model is now based on the sale of its lead product. Following marketing authorization from the European Commission and the UK's MHRA in 2024, Outlook Therapeutics began its commercial launch in Europe, generating its first product sales in the second quarter of 2025. The company's primary focus is on disrupting the wet AMD treatment landscape by providing the first and only FDA-approved ophthalmic formulation of bevacizumab, pending a key regulatory decision in the U.S.